Natera price to sales ratio NTRA

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 21.5×
10-year median: 8.6×
Against its 10-year history: 93rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.8× to 29.3×
Peer median: 6.7×

Natera's price to sales ratio is 21.5× as of Oct 23, 2026.

That is above its ten-year median of 8.6×, higher than on 93% of days in the last ten years.

Over that time it ranged from 1.8× in Apr 2017 to 29.3× in Feb 2021.

The median for 10 diagnostics and research stocks of a similar size is 6.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	21.5×	10.7×	22.0×
2025	15.2×	10.0×	15.9×
2024	13.8×	7.4×	14.8×
2023	7.6×	4.6×	8.0×
2022	5.1×	4.5×	12.6×
2021	15.6×	14.5×	29.3×
2020	23.5×	6.5×	26.4×
2019	9.1×	3.2×	10.8×
2018	3.3×	2.3×	7.5×
2017	2.3×	1.8×	3.7×
2016	2.8×	2.1×	3.4×

Against its peers

Companies in Medical - Diagnostics & Research nearest Natera's size, closest first, today.

Company	Price to sales ratio
NTRANatera	21.5×
AAgilent Technologies	6.6×
IQVIQVIA	2.7×
WATWaters	9.6×
IDXXIDEXX Laboratories	9.7×
ILMNIllumina	9.1×
MTDMettler-Toledo International	8.1×
DGXQuest Diagnostics	2.3×
LHLabcorp	1.9×
DHRDanaher	6.5×
MEDPMedpace	6.7×
Peer median	6.7×

Where Natera ranks

#56of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Natera

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.